GlassScriptPhysician profile
Bryan F Davis
NPI 1639425754
$86,422.86
in general payments reported to CMS, 2019-2025
42 companies · $8,852 in 2025
The $8,852 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $7,051 · 2021: $12K · 2022: $903 · 2023: $21K · 2024: $22K · 2025: $8,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $7,168 · Travel and Lodging: $4,539 · Education: $65.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,250.00 |
| Food and Beverage | $7,168.47 |
| Travel and Lodging | $4,539.35 |
| Education | $65.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $46,550.53 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $31,157.86 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $1,547.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $920.55 | 2022-2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $717.09 | 2021-2025 | Unithroid |
| Medtronic, INC. | $468.43 | 2021-2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.84 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Corcept Therapeutics | $453.75 | 2020-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $336.40 | 2021-2025 | |
| Amgen INC. | $297.05 | 2020-2025 | Evenity, Tepezza, Prolia |
| Sanofi-Aventis U.S. LLC | $292.83 | 2019-2024 | |
| Recordati_rare_diseases_inc. | $271.27 | 2023-2025 | Isturisa, Signifor Lar |
| Insulet Corporation | $261.95 | 2023-2025 | Omnipod |
| Medtronic Minimed, INC. | $257.99 | 2019 | |
| Mannkind Corporation | $235.87 | 2019-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $229.40 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Tandem Diabetes Care, INC. | $226.57 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $221.60 | 2023-2025 | |
| Zealand Pharma US, INC. | $201.00 | 2020-2021 | |
| Valeritas, INC. | $142.90 | 2019 | |
| Ibsa Pharma INC. | $108.97 | 2020-2025 | Licart, Tirosint, Flector |
| Ascensia Diabetes Care US INC. | $101.51 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $89.46 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $87.07 | 2025 | Rezdiffra |
| Companion Medical, INC. | $85.96 | 2020 | |
| Becton, Dickinson and Company | $78.45 | 2020 | |
| Tolmar, INC. | $73.64 | 2023-2025 | Jatenzo |
| Kyowa Kirin, INC. | $63.98 | 2023-2025 | Crysvita |
| Dexcom, INC. | $60.63 | 2025 | Dexcom G6 Transmitter |
| Rgh Enterprises LLC | $49.90 | 2025 | |
| Sequel Med Tech, LLC | $48.34 | 2025 | Twiist |
| Takeda Pharmaceuticals U.S.A., INC. | $45.88 | 2020-2021 | |
| Antares Pharma, INC. | $40.69 | 2025 | Xyosted |
| Abbvie INC. | $40.37 | 2021-2025 | Synthroid |
| Pfizer INC. | $40.34 | 2020-2023 | |
| Cequr Corporation | $32.50 | 2023 | Cequr Simplicity |
| Horizon Therapeutics Plc | $30.15 | 2023 | Tepezza |
| Verity Pharmaceuticals INC. | $29.40 | 2024 | Tlando |
| Ultragenyx Pharmaceutical INC. | $18.03 | 2023 | |
| Lifescan, INC. | $16.44 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $13.71 | 2024 | |
| Arbor Pharmaceuticals, INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.